Apellis Pharmaceuticals, Inc. short interest in 2021
In 2021, Apellis Pharmaceuticals, Inc.'s disclosed short interest ran from 11.81% of shares outstanding on 15 Jan 2021 to 7.66% on 31 Dec 2021, a change of -4.15 percentage points. The year's high was 11.81% on 15 Jan 2021 and its low 5.81% on 13 Aug 2021, averaging 8.17% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.65 days on 26 Feb 2021. Full history: Apellis Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 11.81% (15 Jan 2021)
- End of year
- 7.66% (31 Dec 2021)
- Change
- -4.15 pp
- High
- 11.81% (15 Jan 2021)
- Low
- 5.81% (13 Aug 2021)
- Average
- 8.17%
- Highest days to cover
- 18.65 (26 Feb 2021)
- SEC filings marked
- 4
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 11.81% | 15.65 | |
| 29 Jan 2021 | 10.11% | 11.04 | |
| 12 Feb 2021 | 10.23% | 14.98 | |
| 26 Feb 2021 | 10.71% | 18.65 | 10-K filed |
| 15 Mar 2021 | 9.29% | 13.54 | |
| 31 Mar 2021 | 10.15% | 10.56 | |
| 15 Apr 2021 | 10.62% | 14.13 | |
| 30 Apr 2021 | 9.59% | 13.57 | 10-Q filed |
| 14 May 2021 | 8.57% | 12.10 | |
| 28 May 2021 | 6.97% | 4.20 | |
| 15 Jun 2021 | 7.42% | 10.08 | |
| 30 Jun 2021 | 7.38% | 7.86 | |
| 15 Jul 2021 | 7.74% | 5.69 | |
| 30 Jul 2021 | 6.10% | 6.17 | |
| 13 Aug 2021 | 5.81% | 6.17 | 10-Q filed |
| 31 Aug 2021 | 5.94% | 5.64 | |
| 15 Sep 2021 | 6.57% | 1.18 | |
| 30 Sep 2021 | 7.33% | 4.07 | |
| 15 Oct 2021 | 6.58% | 6.48 | |
| 29 Oct 2021 | 6.84% | 7.43 | |
| 15 Nov 2021 | 6.75% | 4.02 | 10-Q filed |
| 30 Nov 2021 | 7.58% | 4.05 | |
| 15 Dec 2021 | 8.27% | 8.63 | |
| 31 Dec 2021 | 7.66% | 9.06 |
See also: Apellis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.